ClinicalTrials.gg
Active, not recruitingNCT03043872CASPIANUpdated Jul 16, 2026Results posted

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

A Phase 3 interventional study of Durvalumab and Tremelimumab in Small Cell Lung Carcinoma Extensive Disease, sponsored by AstraZeneca. Active, not recruiting at 207 sites in 23 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
987
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing durvalumab in Small Cell Lung Carcinoma — 10 open to participants now, 19 under way, 3 of them phase 3. durvalumab · Small Cell Lung Carcinoma.

Enrollment
Largest of 36
987 · median 50
Started
2017
the only one that year
Phase 3
6 of 36
none open now
Primary completion
2020-01
later than 0 of 18 live
Registered
5th of 36
by date
Lead sponsor
12 of 36
AstraZeneca

Among the 36 studies testing durvalumab in Small Cell Lung Carcinoma, this one has the largest enrollment, is the only one that started in 2017, is one of 6 in phase 3, reaches primary completion later than 0 of the 18 other live ones, and was the 5th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

10 of the 36 studies testing durvalumab in Small Cell Lung Carcinoma are open now, in 8 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing durvalumab in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line treatment in patients with extensive-stage small-cell lung cancer

Read the detailed description

Primary objective of this study is to assess the efficacy of durvalumab + tremelimumab + EP treatment compared with EP and the efficacy of durvalumab + EP treatment compared with EP in terms of OS.

All patients will be randomized in a 1:1:1 ratio in a stratified manner according to the planned platinum-based therapy for Cycle 1 (cisplatin or carboplatin) to receive treatment with durvalumab + tremelimumab + EP (Arm 1), durvalumab + EP (Arm 2), or standard of care- EP (Arm 3). Arm 1 and Arm 2 patients receive the treatment until confirmed disease progression while Arm 3 patients receive up to 6 cycles of EP and prophylactic cranial irradiation if clinically indicated, at the Investigators' discretion.Patients who have discontinued treatment due to toxicity or symptomatic deterioration, clinical progression, or who have commenced subsequent anticancer therapy will be followed up until confirmed disease progression and for survival.

Targeted population are adult patients (aged ≥18 years) with histologically or cytologically documented extensive disease (American Joint Committee on Cancer Stage (7th edition) IV SCLC [T any, N any,M1 a/b]), or T3-4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan. Patients must have WHO/ECOG performance status of 0 or 1.

Tumor assessments will be performed at Screening as baseline with follow-up at Week 6 ±1 week from the date of randomization, at Week 12 ±1 week from the date of randomization, and then every 8 weeks ±1 week until confirmed objective disease progression.

An independent data monitoring committee (IDMC) comprised of independent experts will be convened to confirm the safety and tolerability of the proposed dose and schedule of durvalumab ± tremelimumab in combination with platinum based chemotherapy at two early stages of enrolment.

03

Conditions studied

  • Small Cell Lung Carcinoma Extensive Disease

Keywords

  • Carcinoma, Small Cell Lung
  • Oat Cell Carcinoma of Lung
  • Oat Cell Lung Cancer
  • Small Cell Cancer Of The Lung
  • Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically documented extensive disease. ; must be asymptomatic or treated and stable off and anti-convulsants for at least 1 month prior to study treatment.
  2. Suitable to receive a platinum-based chemotherapy regimen as treatment.
  3. ≥12 weeks at Day 1.
  4. 0 or 1 at enrolment.
  5. No prior exposure to immune-mediated therapy excluding therapeutic anticancer vaccines.

Exclusion criteria

Exclusion criteria:

  1. Any history of radiotherapy to the chest prior to systemic therapy or planned consolidation chest radiation therapy (except paliative care outside of the chest).
  2. Paraneoplastic syndrome of nature, requiring systemic treatment or clinical symptomatology suggesting worsening of PNS
  3. Active infection including tuberculosis, , anc C
  4. Active or prior documented autoimmune or inflammatory disorders
  5. Uncontrolled intercurrent illness, including but not limited to interstitial lung disease.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
987 participants (actual)

Study arms

  • Experimental
    Arm 1

    durvalumab+tremelimumab+EP (carboplatin or cisplatin + etoposide)

    Drug: Durvalumab · Drug: Tremelimumab · Drug: Carboplatin · Drug: Cisplatin · Drug: Etoposide

  • Experimental
    Arm 2

    durvalumab+EP (carboplatin or cisplatin + etoposide)

    Drug: Durvalumab · Drug: Carboplatin · Drug: Cisplatin · Drug: Etoposide

  • Active comparator
    Arm 3

    EP (carboplatin or cisplatin + etoposide)

    Drug: Carboplatin · Drug: Cisplatin · Drug: Etoposide

Interventions

  • IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until PD or other discontinuation criteria.

  • IV infusions every 3 weeks for 12 weeks(4 cycles). An additional dose of tremelimumab will be administered in the week 16.

  • up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3

  • up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3

  • up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS) in the Global Cohort; Assessed at Global Cohort Interim Analysis; D + EP Compared With EP

    OS was defined as the time from date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. An interim analysis of OS in the global cohort was pre-specified after approximately 318 OS events occurred each between the D + EP and EP groups (60% maturity), and between the D + T + EP and EP groups (60% maturity). At the global cohort interim analysis DCO (11 March 2019), comparison of OS in the D + EP versus (vs) EP groups had crossed the pre-specified boundary. Since these results were considered final in terms of formal statistical testing, they are presented here as a primary outcome measure. Analysis of OS for D + EP vs EP and for D + T + EP vs EP at the time of the global cohort final analysis is presented separately in the subsequent primary outcome measure.

    Time frame: From baseline until death due to any cause. Assessed until global cohort interim analysis DCO (maximum of approximately 23 months).

  2. OS in the Global Cohort; Assessed at Global Cohort Final Analysis; D + EP Compared With EP and D + T + EP Compared With EP

    OS was defined as the time from date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. This primary outcome measure presents OS for the analysis of D + EP vs EP and D + T + EP vs EP at the time of the global cohort final analysis DCO (27 January 2020). Analysis of D + EP vs EP at the global cohort interim analysis DCO is presented in the previous primary outcome measure. Analysis of D + T + EP vs D + EP (global cohort final analysis) is presented as a secondary outcome measure.

    Time frame: From baseline until death due to any cause. Assessed until global cohort final analysis DCO (maximum of approximately 33 months).

  3. OS in the China Cohort; Assessed at China Cohort First Analysis; D + EP Compared With EP

    OS was defined as the time from date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. An analysis of OS for D + EP vs EP in the China cohort was pre-specified at approximately 60% maturity (to ensure a similar maturity to the interim analysis of the Global cohort). This primary outcome measure presents OS for analysis of D + EP vs EP at the China cohort first analysis DCO (06 January 2020), and is comparable in terms of maturity with the interim analysis of OS for D + EP vs EP in the Global cohort. Analysis of OS for D + EP vs EP and for D + T + EP vs EP at the time of the China cohort second analysis is presented separately in the subsequent primary outcome measure.

    Time frame: From baseline until death due to any cause. Assessed until China cohort first analysis DCO (maximum of approximately 19 months).

  4. OS in the China Cohort; Assessed at China Cohort Second Analysis; D + EP Compared With EP and D + T + EP Compared With EP

    OS was defined as the time from date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. An analysis of OS for D + T + EP vs EP in the China cohort was pre-specified at approximately 80% maturity (to ensure a similar maturity to the final analysis of the Global cohort). This primary outcome measure presents OS for analysis of D + EP vs EP and D + T + EP vs EP at the time of the China cohort second analysis DCO (02 November 2020), and is comparable in terms of maturity with the final analysis of OS for D + EP vs EP and D + T + EP vs EP in the Global cohort. Analysis of D + EP vs EP at the China cohort first analysis DCO is presented in the previous primary outcome measure. Analysis of D + T + EP vs D + EP (China cohort second analysis) is presented as a secondary outcome measure.

    Time frame: From baseline until death due to any cause. Assessed until China cohort second analysis DCO (maximum of approximately 29 months).

Secondary outcomes

  1. OS in the Global Cohort; D + T + EP Compared With D + EP

    OS was defined as the time from the date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. This secondary outcome measure presents OS for the analysis of D + T + EP vs D + EP in the global cohort. The alternative treatment comparisons in the global cohort were performed as primary outcome measures.

    Time frame: From baseline until death due to any cause. Assessed until global cohort final analysis DCO (maximum of approximately 33 months).

  2. Progression-Free Survival (PFS) in the Global Cohort

    PFS (per Response Evaluation Criteria in Solid Tumors, version 1.1 \[RECIST 1.1\] using Investigator assessments) was defined as time from date of randomization until date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression. Progression (ie, PD) was defined as at least a 20% increase in the sum of diameters of target lesions (TLs), taking as reference the smallest previous sum of diameters (nadir) and an absolute increase of ≥5 millimeters (mm) for the sum from nadir. For evaluation of non-target lesions (NTLs), PD was defined as unequivocal progression of existing NTLs. Median PFS was calculated using the Kaplan-Meier technique.

    Time frame: Tumour scans performed at baseline, Week 6, Week 12 then every 8 weeks relative to the date of randomization until RECIST 1.1-defined progression. Assessed until global cohort final analysis DCO (maximum of approximately 33 months).

  3. Objective Response Rate (ORR) in the Global Cohort

    ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of patients with at least 1 visit response of Complete Response (CR) or Partial Response (PR). CR was defined as disappearance of all TLs since baseline (any pathological lymph nodes selected as TLs must have a reduction in short axis diameter to \<10 mm) or disappearance of all NTLs since baseline (all lymph nodes must be non-pathological in size \[\<10 mm short axis\]). PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters).

    Time frame: Tumour scans performed at baseline, Week 6, Week 12 then every 8 weeks relative to the date of randomization until RECIST 1.1-defined progression. Assessed until global cohort final analysis DCO (maximum of approximately 33 months).

  4. Percentage of Patients Alive and Progression Free at 6 Months (APF6) in the Global Cohort

    The APF6 was defined as the percentage of patients who were alive and progression free at 6 months from randomization (ie, PFS rate at 6 months). PFS was calculated using the Kaplan-Meier technique.

    Time frame: Tumour scans performed at baseline, Week 6, Week 12 then every 8 weeks relative to the date of randomization until RECIST 1.1-defined progression. Assessed until 6 months post-randomization.

  5. Percentage of Patients Alive and Progression Free at 12 Months (APF12) in the Global Cohort

    The APF12 was defined as the percentage of patients who were alive and progression free at 12 months from randomization (ie, PFS rate at 12 months). PFS was calculated using the Kaplan-Meier technique.

    Time frame: Tumour scans performed at baseline, Week 6, Week 12 then every 8 weeks relative to the date of randomization until RECIST 1.1-defined progression. Assessed until 12 months post-randomization.

  6. Percentage of Patients Alive at 18 Months (OS18) in the Global Cohort

    OS18 was defined as the percentage of patients who were alive at 18 months after randomization per the Kaplan-Meier estimate of OS at 18 months.

    Time frame: At 18 months post-randomization. Assessed at the global cohort final analysis DCO (27 January 2020).

  7. Pharmacokinetics (PK) of Durvalumab; Peak and Trough Serum Concentrations in the Global Cohort

    To evaluate PK, blood samples were collected at pre-specified timepoints and peak and trough serum concentrations of durvalumab were determined. Peak concentration on Week 0 is the post-infusion concentration of Week 0 (collected within 10 minutes of the end of infusion). Trough concentrations on Weeks 3 and 12 are the pre-infusion concentrations of Weeks 3 and 12, respectively.

    Time frame: Samples were collected post-dose on Day 1 (Week 0), and pre-dose on Weeks 3 and 12. Assessed at the global cohort final analysis DCO (27 January 2020).

  8. PK of Tremelimumab; Peak and Trough Serum Concentrations in the Global Cohort

    To evaluate PK, blood samples were collected at pre-specified timepoints and peak and trough serum concentrations of tremelimumab were determined. Peak concentration on Week 0 is the post-infusion concentration of Week 0 (collected within 10 minutes of the end of infusion). Trough concentrations on Weeks 3 and 12 are the pre-infusion concentrations of Weeks 3 and 12, respectively.

    Time frame: Samples were collected post-dose on Day 1 (Week 0), and pre-dose on Weeks 3 and 12. Assessed at the global cohort final analysis DCO (27 January 2020).

  9. Number of Patients With Anti-Drug Antibody (ADA) Response to Durvalumab in the Global Cohort

    Serum sampling for ADA assessment was conducted utilizing a tiered approach (screen, confirm, titer). ADA positive post-baseline only was also referred to as treatment-induced ADA. Treatment-emergent ADA was defined as the sum of treatment-induced ADA and treatment-boosted ADA (defined as baseline positive ADA titer that was boosted to ≥4-fold during the study period). Persistently positive was defined as having ≥2 post-baseline ADA positive measurements with ≥16 weeks between first and last positive, or an ADA positive result at the last available assessment. Transiently positive was defined as having ≥1 post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. Presence of neutralizing antibody (nAb) was tested for all ADA positive samples. Results are reported as number of patients with ADA responses to durvalumab for each indicated category.

    Time frame: Samples were collected on Day 1 (Week 0), Week 12 and at 3 months after the last dose of IP (ie, durvalumab). Assessed at the global cohort final analysis DCO (27 January 2020).

  10. Number of Patients With ADA Response to Tremelimumab in the Global Cohort

    Serum sampling for ADA assessment was conducted utilizing a tiered approach (screen, confirm, titer). ADA positive post-baseline only was also referred to as treatment-induced ADA. Treatment-emergent ADA (or ADA incidence) was defined as the sum of treatment-induced ADA and treatment-boosted ADA (defined as baseline positive ADA titer that was boosted to ≥4-fold during the study period). Persistently positive was defined as having ≥2 post-baseline ADA positive measurements with ≥16 weeks between first and last positive, or an ADA positive result at the last available assessment. Transiently positive was defined as having ≥1 post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. The presence of nAb was tested for all ADA positive samples. Results are reported as number of patients with ADA responses to tremelimumab for each indicated category.

    Time frame: Samples were collected on Day 1 (Week 0), Week 12 and at 3 months after the last dose of IP (ie, tremelimumab). Assessed at the global cohort final analysis DCO (27 January 2020).

  11. Time to Deterioration of Health-Related Quality of Life (HRQoL) and Patient Reported Outcome (PRO) Symptoms, Assessed Using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) in the Global Cohort

    The EORTC QLQ-Core 30 version 3 (QLQ-C30 v3) was included for assessing HRQoL. It assesses HRQoL/health status through 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), and a global health and QoL scale. 6 single-item symptom measures are also included: dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties. Scores from 0 to 100 were derived for each of the 15 domains, with higher scores representing greater functioning, greater HRQoL, or greater level of symptoms. Time to deterioration (calculated using the Kaplan-Meier technique) was defined as time from randomization until the date of first clinically meaningful deterioration (a decrease in score from baseline of ≥10) that is confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful deterioration.

    Time frame: At baseline, Weeks 3, 6, 9, 12, 16 and 20, then Q4W until PD, on Day 28 and 2 months post-PD, then every 8 weeks until second progression/death (whichever comes first). Assessed until global cohort final analysis DCO (maximum of approximately 33 months).

  12. Time to Deterioration of PRO Symptoms, Assessed Using EORTC QLQ-Lung Cancer Module 13 (QLQ-LC13) in the Global Cohort

    The EORTC QLQ-LC13 is a disease-specific 13-item self-administered questionnaire for lung cancer, to be used in conjunction with the EORTC QLQ-C30. It comprises both multi-item and single-item measures of lung cancer-associated symptoms (ie, coughing, hemoptysis, dyspnea, and pain) and side effects from conventional chemotherapy and radiotherapy (ie, hair loss, neuropathy, sore mouth, and dysphagia). Scores from 0 to 100 were derived for each symptom item, with higher scores representing greater level of symptoms. Time to deterioration (calculated using the Kaplan-Meier technique) was defined as time from randomization until the date of first clinically meaningful deterioration (an increase in score from baseline of ≥10) that is confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful deterioration.

    Time frame: At baseline, Weeks 3, 6, 9, 12, 16 and 20, then Q4W until PD, on Day 28 and 2 months post-PD, then every 8 weeks until second progression/death (whichever comes first). Assessed until global cohort final analysis DCO (maximum of approximately 33 months).

  13. Change From Baseline in Primary PRO Symptoms as Assessed by EORTC QLQ in the Global Cohort; D + T + EP Compared With EP

    A mixed model repeated measures (MMRM) analysis of EORTC QLQ-C30 and EORTC QLQ-LC13 was performed for 5 primary PRO symptoms (cough, dyspnea, chest pain, fatigue and appetite loss), and considered all data from baseline to PD or 12 months, excluding visits with excessive missing data (defined as \>75% missing data). An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items, with higher scores representing greater symptom severity. An improvement in symptoms was indicated by a negative change from baseline. A positive change from baseline indicated a deterioration of symptoms. A minimum clinically meaningful change was defined as an absolute change from baseline of ≥10. This outcome measure presents change from baseline for primary PRO symptoms (reported as adjusted means) for analysis of D + T + EP vs P. Analysis of D + EP vs EP is presented in a separate outcome measure.

    Time frame: At baseline, Weeks 3, 6, 9, 12, 16 and 20, then Q4W until PD, on Day 28 and 2 months post-PD, then every 8 weeks until second progression/death (whichever comes first). Assessed up to 12 months.

  14. Change From Baseline in Primary Symptoms, Assessed Using EORTC QLQ-C30 and EORTC QLQ-LC13 in the Global Cohort; D + EP Compared With EP

    A MMRM analysis of EORTC QLQ-C30 and EORTC QLQ-LC13 was performed for 5 primary PRO symptoms (cough, dyspnea, chest pain, fatigue and appetite loss), and considered all data from baseline to PD or 12 months, excluding visits with excessive missing data (defined as \>75% missing data). An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items, with higher scores representing greater symptom severity. An improvement in symptoms was indicated by a negative change from baseline. A positive change from baseline indicated a deterioration of symptoms. A minimum clinically meaningful change was defined as an absolute change from baseline of ≥10. This outcome measure presents change from baseline for primary PRO symptoms (reported as adjusted means) for analysis of D + EP vs EP. Analysis of D + T + EP vs EP is presented in a separate outcome measure.

    Time frame: At baseline, Weeks 3, 6, 9, 12, 16 and 20, then Q4W until PD, on Day 28 and 2 months post-PD, then every 8 weeks until second progression/death (whichever comes first). Assessed up to 12 months.

  15. OS in the China Cohort; D + T + EP Compared With D + EP

    OS was defined as the time from the date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. This secondary outcome measure presents OS for the analysis of D + T + EP vs D + EP at the China cohort second analysis DCO (02 November 2020). The alternative treatment comparisons were performed as primary outcome measures.

    Time frame: From baseline until death due to any cause. Assessed until China cohort second analysis DCO (maximum of approximately 29 months).

  16. PFS in the China Cohort

    PFS (per RECIST 1.1 using Investigator assessments) was defined as time from date of randomization until date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression. Progression (ie, PD) was defined as at least a 20% increase in the sum of diameters of TLs, taking as reference the smallest previous sum of diameters (nadir) and an absolute increase of ≥5 mm for the sum from nadir. For evaluation of NTLs, PD was defined as unequivocal progression of existing NTLs. Median PFS was calculated using the Kaplan-Meier technique.

    Time frame: Tumour scans performed at baseline, Week 6, Week 12 then every 8 weeks relative to the date of randomization until RECIST 1.1-defined progression. Assessed until China cohort second analysis DCO (maximum of approximately 29 months).

  17. ORR in the China Cohort

    ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of patients with at least 1 visit response of CR or PR. CR was defined as disappearance of all TLs since baseline (any pathological lymph nodes selected as TLs must have a reduction in short axis diameter to \<10 mm) or disappearance of all NTLs since baseline (all lymph nodes must be non-pathological in size \[\<10 mm short axis\]). PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters).

    Time frame: Tumour scans performed at baseline, Week 6, Week 12 then every 8 weeks relative to the date of randomization until RECIST 1.1-defined progression. Assessed until China cohort second analysis DCO (maximum of approximately 29 months).

  18. APF6 in the China Cohort

    The APF6 was defined as the percentage of patients who were alive and progression free at 6 months from randomization (ie, PFS rate at 6 months). PFS was calculated using the Kaplan-Meier technique.

    Time frame: Tumour scans performed at baseline, Week 6, Week 12 then every 8 weeks relative to the date of randomization until RECIST 1.1-defined progression. Assessed until 6 months post-randomization.

  19. APF12 in the China Cohort

    The APF12 was defined as the percentage of patients who were alive and progression free at 12 months from randomization (ie, PFS rate at 12 months). PFS was calculated using the Kaplan-Meier technique.

    Time frame: Tumour scans performed at baseline, Week 6, Week 12 then every 8 weeks relative to the date of randomization until RECIST 1.1-defined progression. Assessed until 12 months post-randomization.

  20. OS18 in the China Cohort

    OS18 was defined as the percentage of patients who were alive at 18 months after randomization per the Kaplan-Meier estimate of OS at 18 months.

    Time frame: At 18 months post-randomization. Assessed at the China cohort second analysis DCO (02 November 2020).

  21. PK of Durvalumab; Peak and Trough Serum Concentrations in the China Cohort

    To evaluate PK, blood samples were collected at pre-specified timepoints and peak and trough serum concentrations of durvalumab were determined. Peak concentration on Week 0 is the post-infusion concentration of Week 0 (collected within 10 minutes of the end of infusion). Trough concentrations on Weeks 3 and 12 are the pre-infusion concentrations of Weeks 3 and 12, respectively.

    Time frame: Samples were collected post-dose on Day 1 (Week 0), and pre-dose on Weeks 3 and 12. Assessed at the China cohort second analysis DCO (02 November 2020).

  22. PK of Tremelimumab; Peak and Trough Serum Concentrations in the China Cohort

    To evaluate PK, blood samples were collected at pre-specified timepoints and peak and trough serum concentrations of tremelimumab were determined. Peak concentration on Week 0 is the post-infusion concentration of Week 0 (collected within 10 minutes of the end of infusion). Trough concentrations on Weeks 3 and 12 are the pre-infusion concentrations of Weeks 3 and 12, respectively.

    Time frame: Samples were collected post-dose on Day 1 (Week 0), and pre-dose on Weeks 3 and 12. Assessed at the China cohort second analysis DCO (02 November 2020).

  23. Number of Patients With ADA Response to Durvalumab in the China Cohort

    Serum sampling for ADA assessment was conducted utilizing a tiered approach (screen, confirm, titer). ADA positive post-baseline only was also referred to as treatment-induced ADA. Treatment-emergent ADA was defined as the sum of treatment-induced ADA and treatment-boosted ADA (defined as baseline positive ADA titer that was boosted to ≥4-fold during the study period). Persistently positive was defined as having ≥2 post-baseline ADA positive measurements with ≥16 weeks between first and last positive, or an ADA positive result at the last available assessment. Transiently positive was defined as having ≥1 post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. Presence of nAb was tested for all ADA positive samples. Results are reported as number of patients with ADA responses to durvalumab for each indicated category.

    Time frame: Samples were collected on Day 1 (Week 0), Week 12 and at 3 months after the last dose of IP (ie, durvalumab). Assessed at the China cohort second analysis DCO (02 November 2020).

  24. Number of Patients With ADA Response to Tremelimumab in the China Cohort

    Serum sampling for ADA assessment was conducted utilizing a tiered approach (screen, confirm, titer). ADA positive post-baseline only was also referred to as treatment-induced ADA. Treatment-emergent ADA (or ADA incidence) was defined as the sum of treatment-induced ADA and treatment-boosted ADA (defined as baseline positive ADA titer that was boosted to ≥4-fold during the study period). Persistently positive was defined as having ≥2 post-baseline ADA positive measurements with ≥16 weeks between first and last positive, or an ADA positive result at the last available assessment. Transiently positive was defined as having ≥1 post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. The presence of nAb was tested for all ADA positive samples. Results are reported as number of patients with ADA responses to tremelimumab for each indicated category.

    Time frame: Samples were collected on Day 1 (Week 0), Week 12 and at 3 months after the last dose of IP (ie, tremelimumab). Assessed at the China cohort second analysis DCO (02 November 2020).

  25. Time to Deterioration of HRQoL and PRO Symptoms, Assessed Using EORTC QLQ in the China Cohort

    The EORTC QLQ-C30 v3 was included for assessing HRQoL. It assesses HRQoL/health status through 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), and a global health and QoL scale. 6 single-item symptom measures are also included: dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties. Scores from 0 to 100 were derived for each of the 15 domains, with higher scores representing greater functioning, greater HRQoL, or greater level of symptoms. Time to deterioration (calculated using the Kaplan-Meier technique) was defined as time from randomization until the date of first clinically meaningful deterioration (a decrease in score from baseline of ≥10) that is confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful deterioration.

    Time frame: At baseline, Weeks 3, 6, 9, 12, 16 and 20, then Q4W until PD, on Day 28 and 2 months post-PD, then every 8 weeks until second progression/death (whichever comes first). Assessed until China cohort second analysis DCO (maximum of approximately 29 months).

  26. Time to Deterioration of PRO Symptoms, Assessed Using EORTC QLQ-LC13 in the China Cohort

    The EORTC QLQ-LC13 is a disease-specific 13-item self-administered questionnaire for lung cancer, to be used in conjunction with the EORTC QLQ-C30. It comprises both multi-item and single-item measures of lung cancer-associated symptoms (ie, coughing, hemoptysis, dyspnea, and pain) and side effects from conventional chemotherapy and radiotherapy (ie, hair loss, neuropathy, sore mouth, and dysphagia). Scores from 0 to 100 were derived for each symptom item, with higher scores representing greater level of symptoms. Time to deterioration (calculated using the Kaplan-Meier technique) was defined as time from randomization until the date of first clinically meaningful deterioration (an increase in score from baseline of ≥10) that is confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful deterioration.

    Time frame: At baseline, Weeks 3, 6, 9, 12, 16 and 20, then Q4W until PD, on Day 28 and 2 months post-PD, then every 8 weeks until second progression/death (whichever comes first). Assessed until China cohort second analysis DCO (maximum of approximately 29 months).

  27. Change From Baseline in Primary PRO Symptoms, Assessed Using EORTC QLQ-C30 and EORTC QLQ-LC13 in the China Cohort; D + T + EP Compared With EP

    A MMRM analysis of EORTC QLQ-C30 and EORTC QLQ-LC13 was performed for 5 primary PRO symptoms (cough, dyspnea, chest pain, fatigue and appetite loss), and considered all data from baseline to PD or 12 months, excluding visits with excessive missing data (defined as \>75% missing data). An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items, with higher scores representing greater symptom severity. An improvement in symptoms was indicated by a negative change from baseline. A positive change from baseline indicated a deterioration of symptoms. A minimum clinically meaningful change was defined as an absolute change from baseline of ≥10. This outcome measure presents change from baseline for primary PRO symptoms (reported as adjusted means) for analysis of D + T + EP vs EP. Analysis of D + EP vs EP is presented in a separate outcome measure.

    Time frame: At baseline, Weeks 3, 6, 9, 12, 16 and 20, then Q4W until PD, on Day 28 and 2 months post-PD, then every 8 weeks until second progression/death (whichever comes first). Assessed up to 12 months.

  28. Change From Baseline in Primary Symptoms as Assessed by EORTC QLQ in the China Cohort; D + EP Compared With EP

    A MMRM analysis of EORTC QLQ-C30 and EORTC QLQ-LC13 was performed for 5 primary PRO symptoms (cough, dyspnea, chest pain, fatigue and appetite loss), and considered all data from baseline to PD or 12 months, excluding visits with excessive missing data (defined as \>75% missing data). An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items, with higher scores representing greater symptom severity. An improvement in symptoms was indicated by a negative change from baseline. A positive change from baseline indicated a deterioration of symptoms. A minimum clinically meaningful change was defined as an absolute change from baseline of ≥10. This outcome measure presents change from baseline for primary PRO symptoms (reported as adjusted means) for analysis of D + EP vs EP. Analysis of D + T + EP vs EP is presented in a separate outcome measure.

    Time frame: At baseline, Weeks 3, 6, 9, 12, 16 and 20, then Q4W until PD, on Day 28 and 2 months post-PD, then every 8 weeks until second progression/death (whichever comes first). Assessed up to 12 months.

07

Results

Posted Mar 4, 2021
Limitations and caveats
Analysis of the China cohort was performed to evaluate the consistency of efficacy and safety in Chinese patients with the global cohort in order to meet regulatory requirements and was not powered for a formal assessment of statistical significance.

Participant flow

Study was conducted in 209 study centers across 23 countries. It included a global cohort (805 patients) and China cohort (188 patients). China cohort comprised 6 patients also in the global cohort and a further 182 patients randomized after end of global cohort recruitment. Results of the global and China cohorts were reported separately.

Participant flow — Overall Study
MilestoneAll Patients: D + T + EPAll Patients: D + EPAll Patients: EP
Started329328330
Randomized and included in global cohort analysis268268269
Received treatment in global cohort266265266
Randomized and included in china cohort analysis656162
Received treatment in china cohort656162
Included in both cohorts (global + china)411
Ongoing study at global cohort final analysis data cut-off (dco)565631
Ongoing study at china cohort second (final) analysis dco16117
Completed515218
Not completed278276312
Withdrew: Withdrawal by subject6615
Withdrew: Lost to follow-up211
Withdrew: Death270269296

Outcome measures

PrimaryOverall Survival (OS) in the Global Cohort; Assessed at Global Cohort Interim Analysis; D + EP Compared With EP

OS was defined as the time from date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. An interim analysis of OS in the global cohort was pre-specified after approximately 318 OS events occurred each between the D + EP and EP groups (60% maturity), and between the D + T + EP and EP groups (60% maturity). At the global cohort interim analysis DCO (11 March 2019), comparison of OS in the D + EP versus (vs) EP groups had crossed the pre-specified boundary. Since these results were considered final in terms of formal statistical testing, they are presented here as a primary outcome measure. Analysis of OS for D + EP vs EP and for D + T + EP vs EP at the time of the global cohort final analysis is presented separately in the subsequent primary outcome measure.

Time frame:
From baseline until death due to any cause. Assessed until global cohort interim analysis DCO (maximum of approximately 23 months).
Reported as:
Median · months
Overall Survival (OS) in the Global Cohort; Assessed at Global Cohort Interim Analysis; D + EP Compared With EP
monthsGlobal Cohort: D + EPGlobal Cohort: EP
Overall Survival (OS) in the Global Cohort; Assessed at Global Cohort Interim Analysis; D + EP Compared With EP13.0 (11.5 to 14.8)10.3 (9.3 to 11.2)
Statistical analysis
  • Global Cohort: D + EP vs Global Cohort: EP · Log Rank · p = 0.0047 (Analysis was performed using the stratified log-rank test, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and using the rank tests of association approach.) · Hazard ratio (hr): 0.73 · 95% CI 0.591 to 0.909The HR and confidence intervals (CIs) were calculated using a stratified Cox proportional hazards model, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and ties handled by Efron approach.
PrimaryOS in the Global Cohort; Assessed at Global Cohort Final Analysis; D + EP Compared With EP and D + T + EP Compared With EP

OS was defined as the time from date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. This primary outcome measure presents OS for the analysis of D + EP vs EP and D + T + EP vs EP at the time of the global cohort final analysis DCO (27 January 2020). Analysis of D + EP vs EP at the global cohort interim analysis DCO is presented in the previous primary outcome measure. Analysis of D + T + EP vs D + EP (global cohort final analysis) is presented as a secondary outcome measure.

Time frame:
From baseline until death due to any cause. Assessed until global cohort final analysis DCO (maximum of approximately 33 months).
Reported as:
Median · months
OS in the Global Cohort; Assessed at Global Cohort Final Analysis; D + EP Compared With EP and D + T + EP Compared With EP
monthsGlobal Cohort: D + T + EPGlobal Cohort: D + EPGlobal Cohort: EP
OS in the Global Cohort; Assessed at Global Cohort Final Analysis; D + EP Compared With EP and D + T + EP Compared With EP10.4 (9.6 to 12.0)12.9 (11.3 to 14.7)10.5 (9.3 to 11.2)
Statistical analysis
  • Global Cohort: D + EP vs Global Cohort: EP · Log Rank · p = 0.0032 (Analysis was performed using the stratified log-rank test, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and using the rank tests of association approach.) · Hazard ratio (hr): 0.75 · 95% CI 0.625 to 0.910The HR and CIs were calculated using a stratified Cox proportional hazards model, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and ties handled by Efron approach.
  • Global Cohort: D + T + EP vs Global Cohort: EP · Log Rank · p = 0.0451 (Analysis was performed using the stratified log-rank test, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and using the rank tests of association approach.) · Hazard ratio (hr): 0.82 · 95% CI 0.682 to 0.995The HR and CIs were calculated using a stratified Cox proportional hazards model, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and ties handled by Efron approach.
PrimaryOS in the China Cohort; Assessed at China Cohort First Analysis; D + EP Compared With EP

OS was defined as the time from date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. An analysis of OS for D + EP vs EP in the China cohort was pre-specified at approximately 60% maturity (to ensure a similar maturity to the interim analysis of the Global cohort). This primary outcome measure presents OS for analysis of D + EP vs EP at the China cohort first analysis DCO (06 January 2020), and is comparable in terms of maturity with the interim analysis of OS for D + EP vs EP in the Global cohort. Analysis of OS for D + EP vs EP and for D + T + EP vs EP at the time of the China cohort second analysis is presented separately in the subsequent primary outcome measure.

Time frame:
From baseline until death due to any cause. Assessed until China cohort first analysis DCO (maximum of approximately 19 months).
Reported as:
Median · months
OS in the China Cohort; Assessed at China Cohort First Analysis; D + EP Compared With EP
monthsChina Cohort: D + EPChina Cohort: EP
OS in the China Cohort; Assessed at China Cohort First Analysis; D + EP Compared With EP14.4 (12.3 to NA)10.9 (8.9 to 14.0)
Statistical analysis
  • China Cohort: D + EP vs China Cohort: EP · Log Rank · p = 0.0664 (Analysis was performed using the stratified log-rank test, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and using the rank tests of association approach.) · Hazard ratio (hr): 0.65 · 95% CI 0.414 to 1.029The HR and CIs were calculated using a stratified Cox proportional hazards model, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and ties handled by Efron approach.
PrimaryOS in the China Cohort; Assessed at China Cohort Second Analysis; D + EP Compared With EP and D + T + EP Compared With EP

OS was defined as the time from date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. An analysis of OS for D + T + EP vs EP in the China cohort was pre-specified at approximately 80% maturity (to ensure a similar maturity to the final analysis of the Global cohort). This primary outcome measure presents OS for analysis of D + EP vs EP and D + T + EP vs EP at the time of the China cohort second analysis DCO (02 November 2020), and is comparable in terms of maturity with the final analysis of OS for D + EP vs EP and D + T + EP vs EP in the Global cohort. Analysis of D + EP vs EP at the China cohort first analysis DCO is presented in the previous primary outcome measure. Analysis of D + T + EP vs D + EP (China cohort second analysis) is presented as a secondary outcome measure.

Time frame:
From baseline until death due to any cause. Assessed until China cohort second analysis DCO (maximum of approximately 29 months).
Reported as:
Median · months
OS in the China Cohort; Assessed at China Cohort Second Analysis; D + EP Compared With EP and D + T + EP Compared With EP
monthsChina Cohort: D + T + EPChina Cohort: D + EPChina Cohort: EP
OS in the China Cohort; Assessed at China Cohort Second Analysis; D + EP Compared With EP and D + T + EP Compared With EP16.1 (11.3 to 18.6)14.4 (12.3 to 17.0)10.9 (8.9 to 14.0)
Statistical analysis
  • China Cohort: D + EP vs China Cohort: EP · Log Rank · p = 0.1455 (Analysis was performed using the stratified log-rank test, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and using the rank tests of association approach.) · Hazard ratio (hr): 0.75 · 95% CI 0.504 to 1.106The HR and CIs were calculated using a stratified Cox proportional hazards model, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and ties handled by Efron approach.
  • China Cohort: D + T + EP vs China Cohort: EP · Log Rank · p = 0.0314 (Analysis was performed using the stratified log-rank test, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and using the rank tests of association approach.) · Hazard ratio (hr): 0.65 · 95% CI 0.439 to 0.964The HR and CIs were calculated using a stratified Cox proportional hazards model, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and ties handled by Efron approach.
SecondaryOS in the Global Cohort; D + T + EP Compared With D + EP

OS was defined as the time from the date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. This secondary outcome measure presents OS for the analysis of D + T + EP vs D + EP in the global cohort. The alternative treatment comparisons in the global cohort were performed as primary outcome measures.

Time frame:
From baseline until death due to any cause. Assessed until global cohort final analysis DCO (maximum of approximately 33 months).
Reported as:
Median · months
OS in the Global Cohort; D + T + EP Compared With D + EP
monthsGlobal Cohort: D + T + EPGlobal Cohort: D + EP
OS in the Global Cohort; D + T + EP Compared With D + EP10.4 (9.6 to 12.0)12.9 (11.3 to 14.7)
Statistical analysis
  • Global Cohort: D + T + EP vs Global Cohort: D + EP · Log Rank · p = 0.4352 (Analysis was performed using the stratified log-rank test, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and using the rank tests of association approach.) · Hazard ratio (hr): 1.08 · 95% CI 0.890 to 1.309The HR and CIs were calculated using a stratified Cox proportional hazards model, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and ties handled by Efron approach.
SecondaryProgression-Free Survival (PFS) in the Global Cohort

PFS (per Response Evaluation Criteria in Solid Tumors, version 1.1 \[RECIST 1.1\] using Investigator assessments) was defined as time from date of randomization until date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression. Progression (ie, PD) was defined as at least a 20% increase in the sum of diameters of target lesions (TLs), taking as reference the smallest previous sum of diameters (nadir) and an absolute increase of ≥5 millimeters (mm) for the sum from nadir. For evaluation of non-target lesions (NTLs), PD was defined as unequivocal progression of existing NTLs. Median PFS was calculated using the Kaplan-Meier technique.

Time frame:
Tumour scans performed at baseline, Week 6, Week 12 then every 8 weeks relative to the date of randomization until RECIST 1.1-defined progression. Assessed until global cohort final analysis DCO (maximum of approximately 33 months).
Reported as:
Median · months
Progression-Free Survival (PFS) in the Global Cohort
monthsGlobal Cohort: D + T + EPGlobal Cohort: D + EPGlobal Cohort: EP
Progression-Free Survival (PFS) in the Global Cohort4.9 (4.7 to 5.9)5.1 (4.7 to 6.2)5.4 (4.8 to 6.2)
Statistical analysis
  • Global Cohort: D + EP vs Global Cohort: EP · Log Rank · p = 0.0157 (Analysis was performed using the stratified log-rank test, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and using the rank tests of association approach.) · Hazard ratio (hr): 0.80 · 95% CI 0.665 to 0.959The HR and CIs were calculated using a stratified Cox proportional hazards model, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and ties handled by Efron approach.
  • Global Cohort: D + T + EP vs Global Cohort: EP · Log Rank · p = 0.0568 (Analysis was performed using the stratified log-rank test, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and using the rank tests of association approach.) · Hazard ratio (hr): 0.84 · 95% CI 0.696 to 1.005The HR and CIs were calculated using a stratified Cox proportional hazards model, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and ties handled by Efron approach.
  • Global Cohort: D + T + EP vs Global Cohort: D + EP · Log Rank · p = 0.7540 (Analysis was performed using the stratified log-rank test, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and using the rank tests of association approach.) · Hazard ratio (hr): 1.03 · 95% CI 0.857 to 1.235The HR and CIs were calculated using a stratified Cox proportional hazards model, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and ties handled by Efron approach.
SecondaryObjective Response Rate (ORR) in the Global Cohort

ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of patients with at least 1 visit response of Complete Response (CR) or Partial Response (PR). CR was defined as disappearance of all TLs since baseline (any pathological lymph nodes selected as TLs must have a reduction in short axis diameter to \<10 mm) or disappearance of all NTLs since baseline (all lymph nodes must be non-pathological in size \[\<10 mm short axis\]). PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters).

Time frame:
Tumour scans performed at baseline, Week 6, Week 12 then every 8 weeks relative to the date of randomization until RECIST 1.1-defined progression. Assessed until global cohort final analysis DCO (maximum of approximately 33 months).
Reported as:
Number · percentage of patients
Objective Response Rate (ORR) in the Global Cohort
percentage of patientsGlobal Cohort: D + T + EPGlobal Cohort: D + EPGlobal Cohort: EP
Objective Response Rate (ORR) in the Global Cohort74.279.570.6
Statistical analysis
  • Global Cohort: D + EP vs Global Cohort: EP · Regression, Logistic · p = 0.0177 (Analysis was performed using a logistic regression model, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin). P-value is based on twice the change in log-likelihood resulting from addition of a treatment factor to the model.) · Odds ratio (or): 1.61 · 95% CI 1.086 to 2.401
  • Global Cohort: D + T + EP vs Global Cohort: EP · Regression, Logistic · p = 0.3611 (Analysis was performed using a logistic regression model, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin). P-value is based on twice the change in log-likelihood resulting from addition of a treatment factor to the model.) · Odds ratio (or): 1.19 · 95% CI 0.817 to 1.746
SecondaryPercentage of Patients Alive and Progression Free at 6 Months (APF6) in the Global Cohort

The APF6 was defined as the percentage of patients who were alive and progression free at 6 months from randomization (ie, PFS rate at 6 months). PFS was calculated using the Kaplan-Meier technique.

Time frame:
Tumour scans performed at baseline, Week 6, Week 12 then every 8 weeks relative to the date of randomization until RECIST 1.1-defined progression. Assessed until 6 months post-randomization.
Reported as:
Number · percentage of patients
Percentage of Patients Alive and Progression Free at 6 Months (APF6) in the Global Cohort
percentage of patientsGlobal Cohort: D + T + EPGlobal Cohort: D + EPGlobal Cohort: EP
Percentage of Patients Alive and Progression Free at 6 Months (APF6) in the Global Cohort43.2 (37.1 to 49.1)45.4 (39.3 to 51.3)45.8 (39.5 to 51.9)
SecondaryPercentage of Patients Alive and Progression Free at 12 Months (APF12) in the Global Cohort

The APF12 was defined as the percentage of patients who were alive and progression free at 12 months from randomization (ie, PFS rate at 12 months). PFS was calculated using the Kaplan-Meier technique.

Time frame:
Tumour scans performed at baseline, Week 6, Week 12 then every 8 weeks relative to the date of randomization until RECIST 1.1-defined progression. Assessed until 12 months post-randomization.
Reported as:
Number · percentage of patients
Percentage of Patients Alive and Progression Free at 12 Months (APF12) in the Global Cohort
percentage of patientsGlobal Cohort: D + T + EPGlobal Cohort: D + EPGlobal Cohort: EP
Percentage of Patients Alive and Progression Free at 12 Months (APF12) in the Global Cohort16.9 (12.6 to 21.7)17.9 (13.5 to 22.8)5.3 (2.9 to 8.8)
SecondaryPercentage of Patients Alive at 18 Months (OS18) in the Global Cohort

OS18 was defined as the percentage of patients who were alive at 18 months after randomization per the Kaplan-Meier estimate of OS at 18 months.

Time frame:
At 18 months post-randomization. Assessed at the global cohort final analysis DCO (27 January 2020).
Reported as:
Number · percentage of patients
Percentage of Patients Alive at 18 Months (OS18) in the Global Cohort
percentage of patientsGlobal Cohort: D + T + EPGlobal Cohort: D + EPGlobal Cohort: EP
Percentage of Patients Alive at 18 Months (OS18) in the Global Cohort30.7 (25.2 to 36.4)32.0 (26.5 to 37.7)24.8 (19.7 to 30.1)
SecondaryPharmacokinetics (PK) of Durvalumab; Peak and Trough Serum Concentrations in the Global Cohort

To evaluate PK, blood samples were collected at pre-specified timepoints and peak and trough serum concentrations of durvalumab were determined. Peak concentration on Week 0 is the post-infusion concentration of Week 0 (collected within 10 minutes of the end of infusion). Trough concentrations on Weeks 3 and 12 are the pre-infusion concentrations of Weeks 3 and 12, respectively.

Time frame:
Samples were collected post-dose on Day 1 (Week 0), and pre-dose on Weeks 3 and 12. Assessed at the global cohort final analysis DCO (27 January 2020).
Reported as:
Geometric mean · micrograms/milliliter (μg/mL)
Pharmacokinetics (PK) of Durvalumab; Peak and Trough Serum Concentrations in the Global Cohort
micrograms/milliliter (μg/mL)Global Cohort: D + T + EPGlobal Cohort: D + EP
Week 0: peak concentration447.3 ± 78.21502.6 ± 30.52
Week 3: trough concentration91.86 ± 74.36109.5 ± 64.55
Week 12: trough concentration199.2 ± 49.58239.3 ± 50.68
SecondaryPK of Tremelimumab; Peak and Trough Serum Concentrations in the Global Cohort

To evaluate PK, blood samples were collected at pre-specified timepoints and peak and trough serum concentrations of tremelimumab were determined. Peak concentration on Week 0 is the post-infusion concentration of Week 0 (collected within 10 minutes of the end of infusion). Trough concentrations on Weeks 3 and 12 are the pre-infusion concentrations of Weeks 3 and 12, respectively.

Time frame:
Samples were collected post-dose on Day 1 (Week 0), and pre-dose on Weeks 3 and 12. Assessed at the global cohort final analysis DCO (27 January 2020).
Reported as:
Geometric mean · μg/mL
PK of Tremelimumab; Peak and Trough Serum Concentrations in the Global Cohort
μg/mLGlobal Cohort: D + T + EP
Week 0: peak concentration22.77 ± 52.15
Week 3: trough concentration4.245 ± 81.68
Week 12: trough concentration7.576 ± 59.25
SecondaryNumber of Patients With Anti-Drug Antibody (ADA) Response to Durvalumab in the Global Cohort

Serum sampling for ADA assessment was conducted utilizing a tiered approach (screen, confirm, titer). ADA positive post-baseline only was also referred to as treatment-induced ADA. Treatment-emergent ADA was defined as the sum of treatment-induced ADA and treatment-boosted ADA (defined as baseline positive ADA titer that was boosted to ≥4-fold during the study period). Persistently positive was defined as having ≥2 post-baseline ADA positive measurements with ≥16 weeks between first and last positive, or an ADA positive result at the last available assessment. Transiently positive was defined as having ≥1 post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. Presence of neutralizing antibody (nAb) was tested for all ADA positive samples. Results are reported as number of patients with ADA responses to durvalumab for each indicated category.

Time frame:
Samples were collected on Day 1 (Week 0), Week 12 and at 3 months after the last dose of IP (ie, durvalumab). Assessed at the global cohort final analysis DCO (27 January 2020).
Reported as:
Count of participants · Participants
Number of Patients With Anti-Drug Antibody (ADA) Response to Durvalumab in the Global Cohort
ParticipantsGlobal Cohort: D + T + EPGlobal Cohort: D + EP
ADA positive at any visit (ADA prevalence)611
Treatment-emergent ADA positive (ADA incidence)00
Treatment-boosted ADA00
Treatment-induced ADA (ADA positive post-baseline only)00
ADA positive at baseline only611
ADA positive post-baseline and positive at baseline00
Persistently positive00
Transiently positive00
nAb positive at any visit10
SecondaryNumber of Patients With ADA Response to Tremelimumab in the Global Cohort

Serum sampling for ADA assessment was conducted utilizing a tiered approach (screen, confirm, titer). ADA positive post-baseline only was also referred to as treatment-induced ADA. Treatment-emergent ADA (or ADA incidence) was defined as the sum of treatment-induced ADA and treatment-boosted ADA (defined as baseline positive ADA titer that was boosted to ≥4-fold during the study period). Persistently positive was defined as having ≥2 post-baseline ADA positive measurements with ≥16 weeks between first and last positive, or an ADA positive result at the last available assessment. Transiently positive was defined as having ≥1 post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. The presence of nAb was tested for all ADA positive samples. Results are reported as number of patients with ADA responses to tremelimumab for each indicated category.

Time frame:
Samples were collected on Day 1 (Week 0), Week 12 and at 3 months after the last dose of IP (ie, tremelimumab). Assessed at the global cohort final analysis DCO (27 January 2020).
Reported as:
Count of participants · Participants
Number of Patients With ADA Response to Tremelimumab in the Global Cohort
ParticipantsGlobal Cohort: D + T + EP
ADA positive at any visit (ADA prevalence)11
Treatment-emergent ADA positive (ADA incidence)5
Treatment-boosted ADA0
Treatment-induced ADA (ADA positive post-baseline only)5
ADA positive at baseline only6
ADA positive post-baseline and positive at baseline0
Persistently positive4
Transiently positive1
nAb positive at any visit2
SecondaryTime to Deterioration of Health-Related Quality of Life (HRQoL) and Patient Reported Outcome (PRO) Symptoms, Assessed Using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) in the Global Cohort

The EORTC QLQ-Core 30 version 3 (QLQ-C30 v3) was included for assessing HRQoL. It assesses HRQoL/health status through 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), and a global health and QoL scale. 6 single-item symptom measures are also included: dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties. Scores from 0 to 100 were derived for each of the 15 domains, with higher scores representing greater functioning, greater HRQoL, or greater level of symptoms. Time to deterioration (calculated using the Kaplan-Meier technique) was defined as time from randomization until the date of first clinically meaningful deterioration (a decrease in score from baseline of ≥10) that is confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful deterioration.

Time frame:
At baseline, Weeks 3, 6, 9, 12, 16 and 20, then Q4W until PD, on Day 28 and 2 months post-PD, then every 8 weeks until second progression/death (whichever comes first). Assessed until global cohort final analysis DCO (maximum of approximately 33 months).
Reported as:
Median · months
Time to Deterioration of Health-Related Quality of Life (HRQoL) and Patient Reported Outcome (PRO) Symptoms, Assessed Using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) in the Global Cohort
monthsGlobal Cohort: D + T + EPGlobal Cohort: D + EPGlobal Cohort: EP
QLQ-C30 Global Health Status / HRQoL7.2 (5.8 to 8.3)8.4 (7.3 to 11.0)7.4 (6.5 to 9.3)
QLQ-C30 Cognitive Functioning6.0 (5.0 to 7.0)8.4 (7.3 to 10.3)6.0 (5.2 to 7.1)
QLQ-C30 Emotional Functioning7.6 (6.6 to 9.5)11.8 (8.6 to 16.6)7.3 (6.7 to 8.3)
QLQ-C30 Physical Functioning6.0 (5.0 to 6.9)8.4 (7.4 to 12.0)6.5 (6.0 to 8.2)
QLQ-C30 Role Functioning5.0 (4.1 to 6.5)7.4 (5.7 to 10.2)5.9 (4.5 to 6.7)
QLQ-C30 Social Functioning6.2 (5.0 to 7.4)7.4 (6.5 to 8.8)6.3 (4.9 to 7.4)
QLQ-C30 Fatigue4.2 (3.1 to 4.7)5.5 (4.0 to 6.6)4.5 (3.5 to 5.3)
QLQ-C30 Nausea / Vomiting7.5 (6.1 to 8.6)8.4 (6.6 to 10.2)6.6 (5.6 to 7.5)
QLQ-C30 Pain6.9 (6.0 to 7.7)8.0 (6.8 to 10.4)6.7 (6.2 to 7.8)
QLQ-C30 Appetite Loss6.9 (5.6 to 8.5)8.3 (6.8 to 11.0)6.6 (5.5 to 7.5)
QLQ-C30 Constipation8.5 (7.1 to 10.8)11.5 (8.3 to 14.7)7.3 (6.2 to 9.0)
QLQ-C30 Diarrhea8.9 (7.5 to 10.8)14.7 (9.4 to 21.1)7.7 (7.1 to 9.5)
QLQ-C30 Dyspnea7.2 (5.6 to 8.3)9.0 (7.6 to 12.7)7.5 (6.6 to 9.0)
QLQ-C30 Insomnia7.1 (6.1 to 8.6)8.6 (7.1 to 11.8)7.3 (6.4 to 8.3)
SecondaryTime to Deterioration of PRO Symptoms, Assessed Using EORTC QLQ-Lung Cancer Module 13 (QLQ-LC13) in the Global Cohort

The EORTC QLQ-LC13 is a disease-specific 13-item self-administered questionnaire for lung cancer, to be used in conjunction with the EORTC QLQ-C30. It comprises both multi-item and single-item measures of lung cancer-associated symptoms (ie, coughing, hemoptysis, dyspnea, and pain) and side effects from conventional chemotherapy and radiotherapy (ie, hair loss, neuropathy, sore mouth, and dysphagia). Scores from 0 to 100 were derived for each symptom item, with higher scores representing greater level of symptoms. Time to deterioration (calculated using the Kaplan-Meier technique) was defined as time from randomization until the date of first clinically meaningful deterioration (an increase in score from baseline of ≥10) that is confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful deterioration.

Time frame:
At baseline, Weeks 3, 6, 9, 12, 16 and 20, then Q4W until PD, on Day 28 and 2 months post-PD, then every 8 weeks until second progression/death (whichever comes first). Assessed until global cohort final analysis DCO (maximum of approximately 33 months).
Reported as:
Median · months
Time to Deterioration of PRO Symptoms, Assessed Using EORTC QLQ-Lung Cancer Module 13 (QLQ-LC13) in the Global Cohort
monthsGlobal Cohort: D + T + EPGlobal Cohort: D + EPGlobal Cohort: EP
QLQ-LC13 Coughing7.7 (6.9 to 10.8)9.3 (8.0 to 14.1)7.7 (6.7 to 9.5)
QLQ-LC13 Dyspnea6.3 (4.9 to 7.4)6.5 (5.5 to 7.8)5.5 (4.6 to 7.2)
QLQ-LC13 Hemoptysis11.4 (8.9 to 18.6)18.3 (14.5 to NA)10.8 (8.4 to 11.9)
QLQ-LC13 Pain in Arm or Shoulder7.1 (6.3 to 8.3)9.7 (8.1 to 15.1)7.6 (6.6 to 9.3)
QLQ-LC13 Pain in Chest8.5 (7.2 to 10.8)11.5 (8.4 to 15.8)7.9 (7.2 to 9.9)
QLQ-LC13 Pain in Other Parts7.4 (6.5 to 8.7)7.8 (6.6 to 9.3)6.6 (5.1 to 7.5)
SecondaryChange From Baseline in Primary PRO Symptoms as Assessed by EORTC QLQ in the Global Cohort; D + T + EP Compared With EP

A mixed model repeated measures (MMRM) analysis of EORTC QLQ-C30 and EORTC QLQ-LC13 was performed for 5 primary PRO symptoms (cough, dyspnea, chest pain, fatigue and appetite loss), and considered all data from baseline to PD or 12 months, excluding visits with excessive missing data (defined as \>75% missing data). An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items, with higher scores representing greater symptom severity. An improvement in symptoms was indicated by a negative change from baseline. A positive change from baseline indicated a deterioration of symptoms. A minimum clinically meaningful change was defined as an absolute change from baseline of ≥10. This outcome measure presents change from baseline for primary PRO symptoms (reported as adjusted means) for analysis of D + T + EP vs P. Analysis of D + EP vs EP is presented in a separate outcome measure.

Time frame:
At baseline, Weeks 3, 6, 9, 12, 16 and 20, then Q4W until PD, on Day 28 and 2 months post-PD, then every 8 weeks until second progression/death (whichever comes first). Assessed up to 12 months.
Reported as:
Mean · scores on a scale
Change From Baseline in Primary PRO Symptoms as Assessed by EORTC QLQ in the Global Cohort; D + T + EP Compared With EP
scores on a scaleGlobal Cohort: D + T + EPGlobal Cohort: EP
EORTC QLQ-LC13 Cough-15.1 ± 1.74-14.6 ± 1.76
EORTC QLQ-LC13 Dyspnea-6.8 ± 1.60-6.6 ± 1.62
EORTC QLQ-LC13 Chest pain-7.4 ± 1.65-7.0 ± 1.67
EORTC QLQ-C30 Fatigue-6.1 ± 1.84-6.3 ± 1.86
EORTC QLQ-C30 Appetite loss-8.7 ± 2.02-9.5 ± 2.05
SecondaryChange From Baseline in Primary Symptoms, Assessed Using EORTC QLQ-C30 and EORTC QLQ-LC13 in the Global Cohort; D + EP Compared With EP

A MMRM analysis of EORTC QLQ-C30 and EORTC QLQ-LC13 was performed for 5 primary PRO symptoms (cough, dyspnea, chest pain, fatigue and appetite loss), and considered all data from baseline to PD or 12 months, excluding visits with excessive missing data (defined as \>75% missing data). An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items, with higher scores representing greater symptom severity. An improvement in symptoms was indicated by a negative change from baseline. A positive change from baseline indicated a deterioration of symptoms. A minimum clinically meaningful change was defined as an absolute change from baseline of ≥10. This outcome measure presents change from baseline for primary PRO symptoms (reported as adjusted means) for analysis of D + EP vs EP. Analysis of D + T + EP vs EP is presented in a separate outcome measure.

Time frame:
At baseline, Weeks 3, 6, 9, 12, 16 and 20, then Q4W until PD, on Day 28 and 2 months post-PD, then every 8 weeks until second progression/death (whichever comes first). Assessed up to 12 months.
Reported as:
Mean · scores on a scale
Change From Baseline in Primary Symptoms, Assessed Using EORTC QLQ-C30 and EORTC QLQ-LC13 in the Global Cohort; D + EP Compared With EP
scores on a scaleGlobal Cohort: D + EPGlobal Cohort: EP
EORTC QLQ-LC13 Cough-15.0 ± 1.64-15.4 ± 1.72
EORTC QLQ-LC13 Dyspnea-7.1 ± 1.44-6.5 ± 1.50
EORTC QLQ-LC13 Chest pain-7.8 ± 1.59-7.2 ± 1.65
EORTC QLQ-C30 Fatigue-5.8 ± 1.62-4.5 ± 1.69
EORTC QLQ-C30 Appetite loss-10.1 ± 1.73-7.6 ± 1.81
SecondaryOS in the China Cohort; D + T + EP Compared With D + EP

OS was defined as the time from the date of randomization until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique. This secondary outcome measure presents OS for the analysis of D + T + EP vs D + EP at the China cohort second analysis DCO (02 November 2020). The alternative treatment comparisons were performed as primary outcome measures.

Time frame:
From baseline until death due to any cause. Assessed until China cohort second analysis DCO (maximum of approximately 29 months).
Reported as:
Median · months
OS in the China Cohort; D + T + EP Compared With D + EP
monthsChina Cohort: D + T + EPChina Cohort: D + EP
OS in the China Cohort; D + T + EP Compared With D + EP16.1 (11.3 to 18.6)14.4 (12.3 to 17.0)
Statistical analysis
  • China Cohort: D + T + EP vs China Cohort: D + EP · Log Rank · p = 0.4470 (Analysis was performed using the stratified log-rank test, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and using the rank tests of association approach.) · Hazard ratio (hr): 0.86 · 95% CI 0.574 to 1.277The HR and CIs were calculated using a stratified Cox proportional hazards model, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and ties handled by Efron approach.
SecondaryPFS in the China Cohort

PFS (per RECIST 1.1 using Investigator assessments) was defined as time from date of randomization until date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression. Progression (ie, PD) was defined as at least a 20% increase in the sum of diameters of TLs, taking as reference the smallest previous sum of diameters (nadir) and an absolute increase of ≥5 mm for the sum from nadir. For evaluation of NTLs, PD was defined as unequivocal progression of existing NTLs. Median PFS was calculated using the Kaplan-Meier technique.

Time frame:
Tumour scans performed at baseline, Week 6, Week 12 then every 8 weeks relative to the date of randomization until RECIST 1.1-defined progression. Assessed until China cohort second analysis DCO (maximum of approximately 29 months).
Reported as:
Median · months
PFS in the China Cohort
monthsChina Cohort: D + T + EPChina Cohort: D + EPChina Cohort: EP
PFS in the China Cohort5.6 (4.8 to 6.6)4.9 (4.7 to 5.5)5.5 (4.9 to 6.3)
Statistical analysis
  • China Cohort: D + EP vs China Cohort: EP · Log Rank · p = 0.8934 (Analysis was performed using the stratified log-rank test, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and using the rank tests of association approach.) · Hazard ratio (hr): 0.97 · 95% CI 0.661 to 1.437The HR and CIs were calculated using a stratified Cox proportional hazards model, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and ties handled by Efron approach.
  • China Cohort: D + T + EP vs China Cohort: EP · Log Rank · p = 0.1035 (Analysis was performed using the stratified log-rank test, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and using the rank tests of association approach.) · Hazard ratio (hr): 0.72 · 95% CI 0.487 to 1.068The HR and CIs were calculated using a stratified Cox proportional hazards model, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and ties handled by Efron approach.
  • China Cohort: D + T + EP vs China Cohort: D + EP · Log Rank · p = 0.1673 (Analysis was performed using the stratified log-rank test, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and using the rank tests of association approach.) · Hazard ratio (hr): 0.76 · 95% CI 0.522 to 1.116The HR and CIs were calculated using a stratified Cox proportional hazards model, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and ties handled by Efron approach.
SecondaryORR in the China Cohort

ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of patients with at least 1 visit response of CR or PR. CR was defined as disappearance of all TLs since baseline (any pathological lymph nodes selected as TLs must have a reduction in short axis diameter to \<10 mm) or disappearance of all NTLs since baseline (all lymph nodes must be non-pathological in size \[\<10 mm short axis\]). PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters).

Time frame:
Tumour scans performed at baseline, Week 6, Week 12 then every 8 weeks relative to the date of randomization until RECIST 1.1-defined progression. Assessed until China cohort second analysis DCO (maximum of approximately 29 months).
Reported as:
Number · percentage of patients
ORR in the China Cohort
percentage of patientsChina Cohort: D + T + EPChina Cohort: D + EPChina Cohort: EP
ORR in the China Cohort84.678.772.6
Statistical analysis
  • China Cohort: D + EP vs China Cohort: EP · Regression, Logistic · p = 0.4320 (Analysis was performed using a logistic regression model, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin). P-value is based on twice the change in log-likelihood resulting from addition of a treatment factor to the model.) · Odds ratio (or): 1.39 · 95% CI 0.610 to 3.244
  • China Cohort: D + T + EP vs China Cohort: EP · Regression, Logistic · p = 0.0986 (Analysis was performed using a logistic regression model, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin). P-value is based on twice the change in log-likelihood resulting from addition of a treatment factor to the model.) · Odds ratio (or): 2.07 · 95% CI 0.874 to 5.118
SecondaryAPF6 in the China Cohort

The APF6 was defined as the percentage of patients who were alive and progression free at 6 months from randomization (ie, PFS rate at 6 months). PFS was calculated using the Kaplan-Meier technique.

Time frame:
Tumour scans performed at baseline, Week 6, Week 12 then every 8 weeks relative to the date of randomization until RECIST 1.1-defined progression. Assessed until 6 months post-randomization.
Reported as:
Number · percentage of patients
APF6 in the China Cohort
percentage of patientsChina Cohort: D + T + EPChina Cohort: D + EPChina Cohort: EP
APF6 in the China Cohort43.7 (31.2 to 55.5)35.2 (23.3 to 47.4)43.1 (29.8 to 55.7)
SecondaryAPF12 in the China Cohort

The APF12 was defined as the percentage of patients who were alive and progression free at 12 months from randomization (ie, PFS rate at 12 months). PFS was calculated using the Kaplan-Meier technique.

Time frame:
Tumour scans performed at baseline, Week 6, Week 12 then every 8 weeks relative to the date of randomization until RECIST 1.1-defined progression. Assessed until 12 months post-randomization.
Reported as:
Number · percentage of patients
APF12 in the China Cohort
percentage of patientsChina Cohort: D + T + EPChina Cohort: D + EPChina Cohort: EP
APF12 in the China Cohort21.0 (12.0 to 31.9)12.3 (5.4 to 22.2)6.2 (1.6 to 15.3)
SecondaryOS18 in the China Cohort

OS18 was defined as the percentage of patients who were alive at 18 months after randomization per the Kaplan-Meier estimate of OS at 18 months.

Time frame:
At 18 months post-randomization. Assessed at the China cohort second analysis DCO (02 November 2020).
Reported as:
Number · percentage of patients
OS18 in the China Cohort
percentage of patientsChina Cohort: D + T + EPChina Cohort: D + EPChina Cohort: EP
OS18 in the China Cohort40.0 (28.1 to 51.6)36.1 (24.3 to 48.0)23.4 (13.6 to 34.6)
SecondaryPK of Durvalumab; Peak and Trough Serum Concentrations in the China Cohort

To evaluate PK, blood samples were collected at pre-specified timepoints and peak and trough serum concentrations of durvalumab were determined. Peak concentration on Week 0 is the post-infusion concentration of Week 0 (collected within 10 minutes of the end of infusion). Trough concentrations on Weeks 3 and 12 are the pre-infusion concentrations of Weeks 3 and 12, respectively.

Time frame:
Samples were collected post-dose on Day 1 (Week 0), and pre-dose on Weeks 3 and 12. Assessed at the China cohort second analysis DCO (02 November 2020).
Reported as:
Geometric mean · μg/mL
PK of Durvalumab; Peak and Trough Serum Concentrations in the China Cohort
μg/mLChina Cohort: D + T + EPChina Cohort: D + EP
Week 0: peak concentration429.4 ± 19.49432.0 ± 91.79
Week 3: trough concentration81.21 ± 46.1496.24 ± 64.44
Week 12: trough concentration151.0 ± 29.82194.4 ± 53.34
SecondaryPK of Tremelimumab; Peak and Trough Serum Concentrations in the China Cohort

To evaluate PK, blood samples were collected at pre-specified timepoints and peak and trough serum concentrations of tremelimumab were determined. Peak concentration on Week 0 is the post-infusion concentration of Week 0 (collected within 10 minutes of the end of infusion). Trough concentrations on Weeks 3 and 12 are the pre-infusion concentrations of Weeks 3 and 12, respectively.

Time frame:
Samples were collected post-dose on Day 1 (Week 0), and pre-dose on Weeks 3 and 12. Assessed at the China cohort second analysis DCO (02 November 2020).
Reported as:
Geometric mean · μg/mL
PK of Tremelimumab; Peak and Trough Serum Concentrations in the China Cohort
μg/mLChina Cohort: D + T + EP
Week 0: peak concentration24.34 ± 27.05
Week 3: trough concentration4.530 ± 60.60
Week 12: trough concentration9.523 ± 43.94
SecondaryNumber of Patients With ADA Response to Durvalumab in the China Cohort

Serum sampling for ADA assessment was conducted utilizing a tiered approach (screen, confirm, titer). ADA positive post-baseline only was also referred to as treatment-induced ADA. Treatment-emergent ADA was defined as the sum of treatment-induced ADA and treatment-boosted ADA (defined as baseline positive ADA titer that was boosted to ≥4-fold during the study period). Persistently positive was defined as having ≥2 post-baseline ADA positive measurements with ≥16 weeks between first and last positive, or an ADA positive result at the last available assessment. Transiently positive was defined as having ≥1 post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. Presence of nAb was tested for all ADA positive samples. Results are reported as number of patients with ADA responses to durvalumab for each indicated category.

Time frame:
Samples were collected on Day 1 (Week 0), Week 12 and at 3 months after the last dose of IP (ie, durvalumab). Assessed at the China cohort second analysis DCO (02 November 2020).
Reported as:
Count of participants · Participants
Number of Patients With ADA Response to Durvalumab in the China Cohort
ParticipantsChina Cohort: D + T + EPChina Cohort: D + EP
ADA positive at any visit (ADA prevalence)00
Treatment-emergent ADA positive (ADA incidence)00
Treatment-boosted ADA00
Treatment-induced ADA (ADA positive post-baseline only)00
ADA positive at baseline only00
ADA positive post-baseline and positive at baseline00
Persistently positive00
Transiently positive00
nAb positive at any visit00
SecondaryNumber of Patients With ADA Response to Tremelimumab in the China Cohort

Serum sampling for ADA assessment was conducted utilizing a tiered approach (screen, confirm, titer). ADA positive post-baseline only was also referred to as treatment-induced ADA. Treatment-emergent ADA (or ADA incidence) was defined as the sum of treatment-induced ADA and treatment-boosted ADA (defined as baseline positive ADA titer that was boosted to ≥4-fold during the study period). Persistently positive was defined as having ≥2 post-baseline ADA positive measurements with ≥16 weeks between first and last positive, or an ADA positive result at the last available assessment. Transiently positive was defined as having ≥1 post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. The presence of nAb was tested for all ADA positive samples. Results are reported as number of patients with ADA responses to tremelimumab for each indicated category.

Time frame:
Samples were collected on Day 1 (Week 0), Week 12 and at 3 months after the last dose of IP (ie, tremelimumab). Assessed at the China cohort second analysis DCO (02 November 2020).
Reported as:
Count of participants · Participants
Number of Patients With ADA Response to Tremelimumab in the China Cohort
ParticipantsChina Cohort: D + T + EP
ADA positive at any visit (ADA prevalence)3
Treatment-emergent ADA positive (ADA incidence)3
Treatment-boosted ADA0
Treatment-induced ADA (ADA positive post-baseline only)3
ADA positive at baseline only0
ADA positive post-baseline and positive at baseline0
Persistently positive3
Transiently positive0
nAb positive at any visit0
SecondaryTime to Deterioration of HRQoL and PRO Symptoms, Assessed Using EORTC QLQ in the China Cohort

The EORTC QLQ-C30 v3 was included for assessing HRQoL. It assesses HRQoL/health status through 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), and a global health and QoL scale. 6 single-item symptom measures are also included: dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties. Scores from 0 to 100 were derived for each of the 15 domains, with higher scores representing greater functioning, greater HRQoL, or greater level of symptoms. Time to deterioration (calculated using the Kaplan-Meier technique) was defined as time from randomization until the date of first clinically meaningful deterioration (a decrease in score from baseline of ≥10) that is confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful deterioration.

Time frame:
At baseline, Weeks 3, 6, 9, 12, 16 and 20, then Q4W until PD, on Day 28 and 2 months post-PD, then every 8 weeks until second progression/death (whichever comes first). Assessed until China cohort second analysis DCO (maximum of approximately 29 months).
Reported as:
Median · months
Time to Deterioration of HRQoL and PRO Symptoms, Assessed Using EORTC QLQ in the China Cohort
monthsChina Cohort: D + T + EPChina Cohort: D + EPChina Cohort: EP
QLQ-C30 Global Health Status / HRQoL14.5 (6.8 to NA)15.1 (7.6 to NA)7.8 (6.5 to 10.9)
QLQ-C30 Cognitive Functioning7.6 (4.9 to NA)6.8 (2.3 to NA)6.9 (5.7 to NA)
QLQ-C30 Emotional Functioning20.4 (6.8 to NA)15.5 (5.8 to NA)10.0 (6.9 to NA)
QLQ-C30 Physical Functioning21.8 (6.0 to NA)9.3 (5.8 to NA)7.3 (5.7 to 10.9)
QLQ-C30 Role Functioning6.8 (4.9 to 21.3)6.4 (4.2 to 13.9)6.2 (4.1 to 10.0)
QLQ-C30 Social Functioning6.7 (4.3 to 14.1)5.8 (3.9 to 13.3)6.5 (3.3 to 8.3)
QLQ-C30 Fatigue3.7 (2.3 to 6.8)5.3 (2.9 to 9.6)3.9 (2.2 to 5.9)
QLQ-C30 Nausea / Vomiting8.4 (4.7 to NA)9.3 (3.9 to 15.5)8.2 (5.7 to 10.9)
QLQ-C30 Pain6.6 (4.9 to 17.3)6.2 (5.5 to 15.1)6.5 (4.6 to 8.6)
QLQ-C30 Appetite Loss8.4 (2.6 to NA)5.8 (3.3 to NA)6.9 (5.7 to 10.0)
QLQ-C30 ConstipationNA (6.8 to NA)12.0 (5.8 to NA)10.9 (8.6 to NA)
QLQ-C30 Diarrhea17.3 (9.8 to NA)NA (13.3 to NA)10.1 (8.2 to NA)
QLQ-C30 Dyspnea11.6 (6.0 to NA)15.5 (9.3 to NA)7.3 (5.7 to 10.9)
QLQ-C30 Insomnia7.3 (5.2 to NA)15.5 (5.6 to NA)7.8 (6.3 to 10.9)
SecondaryTime to Deterioration of PRO Symptoms, Assessed Using EORTC QLQ-LC13 in the China Cohort

The EORTC QLQ-LC13 is a disease-specific 13-item self-administered questionnaire for lung cancer, to be used in conjunction with the EORTC QLQ-C30. It comprises both multi-item and single-item measures of lung cancer-associated symptoms (ie, coughing, hemoptysis, dyspnea, and pain) and side effects from conventional chemotherapy and radiotherapy (ie, hair loss, neuropathy, sore mouth, and dysphagia). Scores from 0 to 100 were derived for each symptom item, with higher scores representing greater level of symptoms. Time to deterioration (calculated using the Kaplan-Meier technique) was defined as time from randomization until the date of first clinically meaningful deterioration (an increase in score from baseline of ≥10) that is confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful deterioration.

Time frame:
At baseline, Weeks 3, 6, 9, 12, 16 and 20, then Q4W until PD, on Day 28 and 2 months post-PD, then every 8 weeks until second progression/death (whichever comes first). Assessed until China cohort second analysis DCO (maximum of approximately 29 months).
Reported as:
Median · months
Time to Deterioration of PRO Symptoms, Assessed Using EORTC QLQ-LC13 in the China Cohort
monthsChina Cohort: D + T + EPChina Cohort: D + EPChina Cohort: EP
QLQ-LC13 CoughingNA (6.8 to NA)15.5 (5.8 to NA)8.6 (6.8 to NA)
QLQ-LC13 Dyspnea6.9 (3.4 to NA)8.1 (5.3 to 15.5)4.7 (2.5 to 8.6)
QLQ-LC13 HemoptysisNA (17.3 to NA)NA (11.2 to NA)10.1 (6.9 to NA)
QLQ-LC13 Pain in Arm or ShoulderNA (6.9 to NA)15.5 (5.6 to NA)8.6 (6.3 to 10.9)
QLQ-LC13 Pain in ChestNA (6.8 to NA)15.5 (6.8 to NA)10.0 (6.9 to NA)
QLQ-LC13 Pain in Other PartsNA (7.0 to NA)9.3 (6.2 to NA)8.6 (5.7 to 10.9)
SecondaryChange From Baseline in Primary PRO Symptoms, Assessed Using EORTC QLQ-C30 and EORTC QLQ-LC13 in the China Cohort; D + T + EP Compared With EP

A MMRM analysis of EORTC QLQ-C30 and EORTC QLQ-LC13 was performed for 5 primary PRO symptoms (cough, dyspnea, chest pain, fatigue and appetite loss), and considered all data from baseline to PD or 12 months, excluding visits with excessive missing data (defined as \>75% missing data). An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items, with higher scores representing greater symptom severity. An improvement in symptoms was indicated by a negative change from baseline. A positive change from baseline indicated a deterioration of symptoms. A minimum clinically meaningful change was defined as an absolute change from baseline of ≥10. This outcome measure presents change from baseline for primary PRO symptoms (reported as adjusted means) for analysis of D + T + EP vs EP. Analysis of D + EP vs EP is presented in a separate outcome measure.

Time frame:
At baseline, Weeks 3, 6, 9, 12, 16 and 20, then Q4W until PD, on Day 28 and 2 months post-PD, then every 8 weeks until second progression/death (whichever comes first). Assessed up to 12 months.
Reported as:
Mean · scores on a scale
Change From Baseline in Primary PRO Symptoms, Assessed Using EORTC QLQ-C30 and EORTC QLQ-LC13 in the China Cohort; D + T + EP Compared With EP
scores on a scaleChina Cohort: D + T + EPChina Cohort: EP
EORTC QLQ-LC13 Cough-12.8 ± 2.49-12.9 ± 2.50
EORTC QLQ-LC13 Dyspnea-3.6 ± 2.21-0.8 ± 2.17
EORTC QLQ-LC13 Chest pain-5.1 ± 2.16-5.4 ± 2.16
EORTC QLQ-C30 Fatigue2.8 ± 2.102.9 ± 2.11
EORTC QLQ-C30 Appetite loss3.0 ± 2.360.8 ± 2.42
SecondaryChange From Baseline in Primary Symptoms as Assessed by EORTC QLQ in the China Cohort; D + EP Compared With EP

A MMRM analysis of EORTC QLQ-C30 and EORTC QLQ-LC13 was performed for 5 primary PRO symptoms (cough, dyspnea, chest pain, fatigue and appetite loss), and considered all data from baseline to PD or 12 months, excluding visits with excessive missing data (defined as \>75% missing data). An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items, with higher scores representing greater symptom severity. An improvement in symptoms was indicated by a negative change from baseline. A positive change from baseline indicated a deterioration of symptoms. A minimum clinically meaningful change was defined as an absolute change from baseline of ≥10. This outcome measure presents change from baseline for primary PRO symptoms (reported as adjusted means) for analysis of D + EP vs EP. Analysis of D + T + EP vs EP is presented in a separate outcome measure.

Time frame:
At baseline, Weeks 3, 6, 9, 12, 16 and 20, then Q4W until PD, on Day 28 and 2 months post-PD, then every 8 weeks until second progression/death (whichever comes first). Assessed up to 12 months.
Reported as:
Mean · scores on a scale
Change From Baseline in Primary Symptoms as Assessed by EORTC QLQ in the China Cohort; D + EP Compared With EP
scores on a scaleChina Cohort: D + EPChina Cohort: EP
EORTC QLQ-LC13 Cough-14.9 ± 2.66-16.7 ± 2.68
EORTC QLQ-LC13 Dyspnea-2.2 ± 1.93-3.0 ± 1.97
EORTC QLQ-LC13 Chest pain-6.7 ± 1.93-7.7 ± 1.95
EORTC QLQ-C30 Fatigue1.5 ± 2.060.8 ± 2.11
EORTC QLQ-C30 Appetite loss3.6 ± 2.47-2.2 ± 2.51

Adverse events

Collected over All treatment-emergent adverse events (TEAEs) were collected up to the final analysis DCO for each cohort; maximum of approximately 33 months for the Global cohort and maximum of approximately 29 months for the China cohort. Serious AEs and Deaths were collected through LTFU analysis in patients still receiving durvalumab (or within 90 days of discontinuing treatment); up to approximately 4 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Global Cohort: D + T + EP225/266 (84.6%)126/266 (47.4%)249/266 (93.6%)
Global Cohort: D + EP218/265 (82.3%)86/265 (32.5%)247/265 (93.2%)
Global Cohort: EP247/266 (92.9%)97/266 (36.5%)248/266 (93.2%)
China Cohort: D + T + EP50/65 (76.9%)31/65 (47.7%)65/65 (100%)
China Cohort: D + EP51/61 (83.6%)26/61 (42.6%)61/61 (100%)
China Cohort: EP55/62 (88.7%)22/62 (35.5%)61/62 (98.4%)
Most frequent serious events
Showing 10 of 238
Most frequent serious events
EventGlobal Cohort: D + T + EPGlobal Cohort: D + EPGlobal Cohort: EPChina Cohort: D + T + EPChina Cohort: D + EPChina Cohort: EP
PneumoniaInfections and infestations16/2666/26511/2669/655/612/62
Bone marrow failureBlood and lymphatic system disorders0/2660/2650/2665/656/617/62
NeutropeniaBlood and lymphatic system disorders5/2662/2657/2660/651/613/62
ThrombocytopeniaBlood and lymphatic system disorders6/2661/2659/2663/650/611/62
Febrile neutropeniaBlood and lymphatic system disorders11/26612/26512/2662/650/610/62
AnaemiaBlood and lymphatic system disorders9/2665/26512/2662/650/612/62
HyponatraemiaMetabolism and nutrition disorders9/2662/2654/2661/652/612/62
Cardiac failureCardiac disorders2/2660/2650/2660/652/610/62
DeathGeneral disorders4/2660/2652/2661/652/612/62
PyrexiaGeneral disorders0/2660/2652/2660/652/610/62
Most frequent other events
Showing 10 of 72
Most frequent other events
EventGlobal Cohort: D + T + EPGlobal Cohort: D + EPGlobal Cohort: EPChina Cohort: D + T + EPChina Cohort: D + EPChina Cohort: EP
AnaemiaBlood and lymphatic system disorders94/26697/265116/26647/6544/6144/62
LeukopeniaBlood and lymphatic system disorders33/26640/26532/26628/6531/6122/62
NauseaGastrointestinal disorders85/26689/26588/26631/6520/6127/62
AlopeciaSkin and subcutaneous tissue disorders79/26684/26592/26628/6529/6127/62
VomitingGastrointestinal disorders36/26639/26542/26630/6519/6123/62
Neutrophil count decreasedInvestigations11/26626/26531/26622/6528/6121/62
NeutropeniaBlood and lymphatic system disorders112/266110/265119/26626/6522/6119/62
Decreased appetiteMetabolism and nutrition disorders57/26648/26546/26627/6527/6127/62
ConstipationGastrointestinal disorders54/26643/26552/26625/6524/6122/62
White blood cell count decreasedInvestigations9/26614/26517/26616/6517/6124/62

Baseline characteristics

Baseline analysis was based on the global full analysis set (FAS) (all patients randomized prior to the end of global recruitment) plus the China FAS (all randomized patients in the China cohort). Patients included in both cohorts are not double-counted for the baseline analysis represented by 'All Patients'.

Age, Customized
Age, Customized(Participants)All Patients: D + T + EPAll Patients: D + EPAll Patients: EPTotal
Al Patients — <5021132862
Al Patients — ≥50 to <65175195169539
Al Patients — ≥65 to <7510898110316
Al Patients — ≥7525222370
Global Cohort — <5016102046
Global Cohort — ≥50 to <65138157137432
Global Cohort — ≥65 to <75918290263
Global Cohort — ≥7523192264
China Cohort — <5053816
China Cohort — ≥50 to <65403933112
China Cohort — ≥65 to <7517162053
China Cohort — ≥753317
Sex: Female, Male
Sex: Female, Male(Participants)All Patients: D + T + EPAll Patients: D + EPAll Patients: EPTotal
All Patients — Female748695255
All Patients — Male255242235732
Global Cohort — Female667885229
Global Cohort — Male202190184576
China Cohort — Female891027
China Cohort — Male575252161
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Patients: D + T + EPAll Patients: D + EPAll Patients: EPTotal
All Patients — Hispanic or Latino710623
All Patients — Not Hispanic or Latino321315322958
All Patients — Unknown or Not Reported1326
Global Cohort — Hispanic or Latino710623
Global Cohort — Not Hispanic or Latino260255261776
Global Cohort — Unknown or Not Reported1326
China Cohort — Hispanic or Latino0000
China Cohort — Not Hispanic or Latino656162188
China Cohort — Unknown or Not Reported0000
Race
Race(Participants)All Patients: D + T + EPAll Patients: D + EPAll Patients: EPTotal
All Patients — White215229221665
All Patients — Black or African American1236
All Patients — Asian10896103307
All Patients — Other5128
All Patients — Missing0011
Global Cohort — White215229221665
Global Cohort — Black or African American1236
Global Cohort — Asian473642125
Global Cohort — Other5128
Global Cohort — Missing0011
China Cohort — White0000
China Cohort — Black or African American0000
China Cohort — Asian656162188
China Cohort — Other0000
China Cohort — Missing0000
08

Study locations

207 sites
  • Research Site
    Birmingham, Alabama 35235, United States
  • Research Site
    Scottsdale, Arizona 85259, United States
  • Research Site
    Rogers, Arkansas 72758, United States
  • Research Site
    Santa Monica, California 90404, United States
  • Research Site
    New Haven, Connecticut 06520, United States
  • Research Site
    Athens, Georgia 30607, United States
  • Research Site
    Fort Wayne, Indiana 46804, United States
  • Research Site
    Muncie, Indiana 47303, United States
  • Research Site
    Leawood, Kansas 66209, United States
  • Research Site
    Wichita, Kansas 67214, United States
  • Research Site
    Paducah, Kentucky 42003, United States
  • Research Site
    Grand Rapids, Michigan 49503, United States
  • Research Site
    Mineola, New York 11501, United States
  • Research Site
    Cleveland, Ohio 44106, United States
  • Research Site
    Columbus, Ohio 43219, United States
  • Research Site
    Harrisburg, Pennsylvania 17109, United States
  • Research Site
    Sioux Falls, South Dakota 57104, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Kennewick, Washington 99336, United States
  • Research Site
    Buenos Aires, C1118AAT, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1426, Argentina
  • Research Site
    Mar del Plata, 7600, Argentina
  • Research Site
    Rosario, 2000, Argentina
  • Research Site
    San Miguel de Tucumán, T4000IAK, Argentina
  • Research Site
    Linz, 4021, Austria
  • Research Site
    Salzburg, 5020, Austria
  • Research Site
    Vienna, 1140, Austria
  • Research Site
    Vienna, 1210, Austria
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Curitiba, 81520-060, Brazil
  • Research Site
    Passo Fundo, 99010 260, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Ribeirão Preto, 14048-900, Brazil
  • Research Site
    Rio de Janeiro, 22793-080, Brazil
  • Research Site
    Salvador, 41.950-610, Brazil
  • Research Site
    Santo André, 09060-650, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 03102-002, Brazil
  • Research Site
    Panagyurishte, 4500, Bulgaria
  • Research Site
    Plovdiv, 4000, Bulgaria
  • Research Site
    Plovdiv, 4004, Bulgaria
  • Research Site
    Sofia, 1330, Bulgaria
  • Research Site
    Sofia, 1431, Bulgaria
  • Research Site
    Sofia, 1618, Bulgaria
  • Research Site
    Sofia, 1784, Bulgaria
  • Research Site
    Varna, 9010, Bulgaria
  • Research Site
    Beijing, 100142, China
  • Research Site
    Beijing, 100730, China
  • Research Site
    Beijing, 100853, China
  • Research Site
    Bengbu, 233004, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chongqing, 400038, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310006, China
  • Research Site
    Hangzhou, 310009, China
  • Research Site
    Hefei, 230601, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 200433, China
  • Research Site
    Shenyang, 110042, China
  • Research Site
    Ürümqi, 830000, China
  • Research Site
    Wenzhou, 325000, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Xi'an, 710038, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Zhanjiang, 524001, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Zhuhai, 519099, China
  • Research Site
    Brno, 639 00, Czechia
  • Research Site
    Olomouc, 775 21, Czechia
  • Research Site
    Ostrava - Vitkovice, 703 84, Czechia
  • Research Site
    Prague, 128 08, Czechia
  • Research Site
    Prague, 140 59, Czechia
  • Research Site
    Prague, CZ-150 18, Czechia
  • Research Site
    Avignon, 84918, France
  • Research Site
    Brest, 29609, France
  • Research Site
    Créteil, 94010, France
  • Research Site
    La Tronche, 38043, France
  • Research Site
    Pierre-Bénite, 69310, France
  • Research Site
    Rennes, 35033, France
  • Research Site
    Aachen, 52074, Germany
  • Research Site
    Berlin, 13125, Germany
  • Research Site
    Gauting, 82131, Germany
  • Research Site
    Gera, 07548, Germany
  • Research Site
    Hamburg, 20251, Germany
  • Research Site
    Heidelberg, 69126, Germany
  • Research Site
    Mainz, 55131, Germany
  • Research Site
    Regensburg, 93053, Germany
  • Research Site
    Budapest, 1083, Hungary
  • Research Site
    Budapest, 1106, Hungary
  • Research Site
    Budapest, 1121, Hungary
  • Research Site
    Budapest, 1134, Hungary
  • Research Site
    Deszk, 6772, Hungary
  • Research Site
    Gyula, 5700, Hungary
  • Research Site
    Kaposvár, 7400, Hungary

Showing the first 100 of 207 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ozguroglu M, Goldman JW, Chen Y, Garassino MC, Medic N, Mann H, Chugh P, Dalvi T, Paz-Ares L. Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study. Future Oncol. 2025 May;21(12):1511-1523. doi: 10.1080/14796694.2025.2491297. Epub 2025 May 7. PubMed 40331625 ↗
  • Xie M, Vuko M, Rodriguez-Canales J, Zimmermann J, Schick M, O'Brien C, Paz-Ares L, Goldman JW, Garassino MC, Gay CM, Heymach JV, Jiang H, Barrett JC, Stewart RA, Lai Z, Byers LA, Rudin CM, Shrestha Y. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study. Mol Cancer. 2024 May 30;23(1):115. doi: 10.1186/s12943-024-02014-x. PubMed 38811992 ↗
  • Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Ozguroglu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4. PubMed 33285097 ↗
  • Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Ozguroglu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4. PubMed 31590988 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Jan 2020, 34 months.

Results were first posted in Mar 2021, 1 year 1 month after primary completion.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's 34 months is close to that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2017
First posted
Feb 6, 2017
StartActual
Mar 27, 2017
Primary completionActual
Jan 27, 2020
CompletionEst.
Dec 31, 2026
Results first posted
Mar 4, 2021
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03043872
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 6, 2017
Start date
Mar 27, 2017
Primary completion
Jan 27, 2020
Completion
Dec 31, 2026 (estimated)
Results posted
Mar 4, 2021
Last update
Jul 16, 2026

Study contacts

Haiyi Jiang, M.D.
study director · AstraZeneca

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Tremelimumab

Start the discussion